TNFRSF9 and interstitial lung disease: Although some researchers have reported a high risk of acute exacerbation caused by molecular-targeted agents among patients with lung cancer and coexisting ILD [25, 26], tyrosine kinase inhibitors are still administered to selected patients, especially patients with NSCLC and ILA [26, 27].